Remit: To appraise the clinical and cost-effectiveness of atezolizumab within its marketing authorisation for non-small cell lung cancer
 
Status Suspended
Process TAG

Timeline

Key events during the development of the guidance:

Date Update
11 October 2019 Suspended. Remit: To appraise the clinical and cost-effectiveness of atezolizumab within its marketing authorisation for non-small cell lung cancer
11 October 2019 The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance